AustralieFrV1, Main, Exploration, bibRecord, 005859

Ten Years of Experience with Biphasic Insulin Aspart 30: From Drug Development to the Latest Clinical Findings

Identifieur interne : 005859 ( Main/Exploration ); précédent : 005858; suivant : 005860

Ten Years of Experience with Biphasic Insulin Aspart 30: From Drug Development to the Latest Clinical Findings

Auteurs : Andreas Liebl [Allemagne] ; Vinay Prusty [Suisse] ; Paul Valensi [France] ; Ryuzo Kawamori [Japon] ; Jens Sandahl Christiansen [Danemark] ; Andrew J. Palmer [Australie] ; Per Balschmidt [Danemark] ; Robert Ligthelm [Pays-Bas] ; Viswanathan Mohan [Inde]

Source :

Drugs : (Basel) [ 0012-6667 ] ; 2012.

RBID : Pascal:12-0426451

Descripteurs français

Pascal (Inist)
- Insuline asparte, Recherche et développement, Soluté injectable d'insuline biphasique, Symptomatologie, Article synthèse, Traitement, Homme, Toxicité, Diabète, Hypoglycémiant.
Wicri :
- topic : Recherche et développement, Homme, Diabète.

English descriptors

KwdEn :
- Biphasic insulin injection, Diabetes mellitus, Human, Hypoglycemic agent, Insulin aspart, Research and development, Review, Symptomatology, Toxicity, Treatment.

Abstract

Biphasic insulin aspart 30 (BIAsp 30) includes 30% soluble rapid-acting insulin aspart (IAsp) along with an intermediate-acting 70% protaminated IAsp that provides coverage of prandial and basal insulin in a single injection. As BIAsp 30 has been available internationally for 10 years, this review provides a comprehensive overview of the discovery of BIAsp 30, its pharmacokinetic and pharmacodynamic profile, safety and efficacy outcomes from the clinical trial programme, 'real-life' clinical insights provided by observational study data, and cost effectiveness and quality-of-life information. These studies have demonstrated that BIAsp 30 once or twice daily is an appropriate option for insulin initiation. BIAsp 30 also provides a switch option in patients on biphasic human insulin (BHI). Switching from BHI to BIAsp 30 is associated with improved postprandial glucose (PPG) and reduced nocturnal and major hypoglycaemia, although daytime hypoglycaemia is higher with BIAsp 30. Intensification of BIAsp 30 can be achieved by increasing the number of daily doses up to three times daily with meals. Therefore, BIAsp 30 provides an intensification option for individuals who are not achieving control with basal insulin and would prefer the simplicity of a single biphasic insulin instead of progressing to a basal-bolus approach. BIAsp 30 has a simple dose-titration algorithm, which enables patients to effectively self-titrate their insulin dose. Cost-effectiveness analyses have demonstrated that BIAsp 30 is cost effective or dominant compared with BHI 30 or insulin glargine in a number of healthcare settings. In conclusion, BIAsp 30 offers a simple and flexible option for insulin initiation and intensification that provides coverage of both fasting and prandial glucose.

Url:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3590411

Affiliations:

Allemagne, Australie, Danemark, France, Inde, Japon, Pays-Bas, Suisse
Hollande-Méridionale, Région de Kantō, Île-de-France
Paris, Rotterdam, Tokyo

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Ten Years of Experience with Biphasic Insulin Aspart 30: From Drug Development to the Latest Clinical Findings</title>
<author><name sortKey="Liebl, Andreas" sort="Liebl, Andreas" uniqKey="Liebl A" first="Andreas" last="Liebl">Andreas Liebl</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Fachklinik Bad Heilbrunn</s1>
<s2>Bad Heilbrunn</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>Bad Heilbrunn</wicri:noRegion>
<wicri:noRegion>Fachklinik Bad Heilbrunn</wicri:noRegion>
<wicri:noRegion>Fachklinik Bad Heilbrunn</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Prusty, Vinay" sort="Prusty, Vinay" uniqKey="Prusty V" first="Vinay" last="Prusty">Vinay Prusty</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Novo Nordisk A/S</s1>
<s2>Zurich</s2>
<s3>CHE</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Suisse</country>
<wicri:noRegion>Novo Nordisk A/S</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Valensi, Paul" sort="Valensi, Paul" uniqKey="Valensi P" first="Paul" last="Valensi">Paul Valensi</name>
<affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Department of Endocrinology Diabetology Nutrition, Paris Nord University, Jean Verdier Hospital, Assistance Publique - Hôpitaux De Paris (AP-HP), Centre De Recherche en Nutrition Humaine - He de France (CRNH-IdF)</s1>
<s2>Bondy, Paris</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kawamori, Ryuzo" sort="Kawamori, Ryuzo" uniqKey="Kawamori R" first="Ryuzo" last="Kawamori">Ryuzo Kawamori</name>
<affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Department of Metabolism and Endocrinology, Juntendo University School of Medicine</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Christiansen, Jens Sandahl" sort="Christiansen, Jens Sandahl" uniqKey="Christiansen J" first="Jens Sandahl" last="Christiansen">Jens Sandahl Christiansen</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Endocrinology-M, Aarhus University Hospital</s1>
<s2>Aarhus</s2>
<s3>DNK</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Danemark</country>
<wicri:noRegion>Aarhus</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Palmer, Andrew J" sort="Palmer, Andrew J" uniqKey="Palmer A" first="Andrew J." last="Palmer">Andrew J. Palmer</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Menzies Research Institute Tasmania, University of Tasmania</s1>
<s2>Hobart, Tasmania</s2>
<s3>AUS</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Hobart, Tasmania</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Balschmidt, Per" sort="Balschmidt, Per" uniqKey="Balschmidt P" first="Per" last="Balschmidt">Per Balschmidt</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Novo Nordisk A/S</s1>
<s2>Måløv</s2>
<s3>DNK</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Danemark</country>
<wicri:noRegion>Novo Nordisk A/S</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ligthelm, Robert" sort="Ligthelm, Robert" uniqKey="Ligthelm R" first="Robert" last="Ligthelm">Robert Ligthelm</name>
<affiliation wicri:level="3"><inist:fA14 i1="08"><s1>EHM Clinic</s1>
<s2>Rotterdam</s2>
<s3>NLD</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
<placeName><settlement type="city">Rotterdam</settlement>
<region nuts="2" type="province">Hollande-Méridionale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mohan, Viswanathan" sort="Mohan, Viswanathan" uniqKey="Mohan V" first="Viswanathan" last="Mohan">Viswanathan Mohan</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Dr Mohan's Diabetes Specialities Centre</s1>
<s2>Gopalapuram, Chennai</s2>
<s3>IND</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Inde</country>
<wicri:noRegion>Dr Mohan's Diabetes Specialities Centre</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">12-0426451</idno>
<date when="2012">2012</date>
<idno type="stanalyst">PASCAL 12-0426451 INIST</idno>
<idno type="RBID">Pascal:12-0426451</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000F01</idno>
<idno type="wicri:Area/PascalFrancis/Curation">005020</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000D06</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000D06</idno>
<idno type="wicri:doubleKey">0012-6667:2012:Liebl A:ten:years:of</idno>
<idno type="wicri:Area/Main/Merge">005B41</idno>
<idno type="wicri:source">PMC</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3590411</idno>
<idno type="RBID">PMC:3590411</idno>
<idno type="wicri:Area/Pmc/Corpus">000E86</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000E86</idno>
<idno type="wicri:Area/Pmc/Curation">000D47</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000D47</idno>
<idno type="wicri:Area/Pmc/Checkpoint">001D55</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">001D55</idno>
<idno type="wicri:Area/Ncbi/Merge">000F01</idno>
<idno type="wicri:Area/Ncbi/Curation">000F01</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000F01</idno>
<idno type="wicri:doubleKey">0012-6667:2012:Liebl A:ten:years:of</idno>
<idno type="wicri:Area/Main/Merge">005446</idno>
<idno type="wicri:Area/Main/Curation">005859</idno>
<idno type="wicri:Area/Main/Exploration">005859</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Ten Years of Experience with Biphasic Insulin Aspart 30: From Drug Development to the Latest Clinical Findings</title>
<author><name sortKey="Liebl, Andreas" sort="Liebl, Andreas" uniqKey="Liebl A" first="Andreas" last="Liebl">Andreas Liebl</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Fachklinik Bad Heilbrunn</s1>
<s2>Bad Heilbrunn</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>Bad Heilbrunn</wicri:noRegion>
<wicri:noRegion>Fachklinik Bad Heilbrunn</wicri:noRegion>
<wicri:noRegion>Fachklinik Bad Heilbrunn</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Prusty, Vinay" sort="Prusty, Vinay" uniqKey="Prusty V" first="Vinay" last="Prusty">Vinay Prusty</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Novo Nordisk A/S</s1>
<s2>Zurich</s2>
<s3>CHE</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Suisse</country>
<wicri:noRegion>Novo Nordisk A/S</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Valensi, Paul" sort="Valensi, Paul" uniqKey="Valensi P" first="Paul" last="Valensi">Paul Valensi</name>
<affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Department of Endocrinology Diabetology Nutrition, Paris Nord University, Jean Verdier Hospital, Assistance Publique - Hôpitaux De Paris (AP-HP), Centre De Recherche en Nutrition Humaine - He de France (CRNH-IdF)</s1>
<s2>Bondy, Paris</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kawamori, Ryuzo" sort="Kawamori, Ryuzo" uniqKey="Kawamori R" first="Ryuzo" last="Kawamori">Ryuzo Kawamori</name>
<affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Department of Metabolism and Endocrinology, Juntendo University School of Medicine</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Christiansen, Jens Sandahl" sort="Christiansen, Jens Sandahl" uniqKey="Christiansen J" first="Jens Sandahl" last="Christiansen">Jens Sandahl Christiansen</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Endocrinology-M, Aarhus University Hospital</s1>
<s2>Aarhus</s2>
<s3>DNK</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Danemark</country>
<wicri:noRegion>Aarhus</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Palmer, Andrew J" sort="Palmer, Andrew J" uniqKey="Palmer A" first="Andrew J." last="Palmer">Andrew J. Palmer</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Menzies Research Institute Tasmania, University of Tasmania</s1>
<s2>Hobart, Tasmania</s2>
<s3>AUS</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Hobart, Tasmania</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Balschmidt, Per" sort="Balschmidt, Per" uniqKey="Balschmidt P" first="Per" last="Balschmidt">Per Balschmidt</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Novo Nordisk A/S</s1>
<s2>Måløv</s2>
<s3>DNK</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Danemark</country>
<wicri:noRegion>Novo Nordisk A/S</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ligthelm, Robert" sort="Ligthelm, Robert" uniqKey="Ligthelm R" first="Robert" last="Ligthelm">Robert Ligthelm</name>
<affiliation wicri:level="3"><inist:fA14 i1="08"><s1>EHM Clinic</s1>
<s2>Rotterdam</s2>
<s3>NLD</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
<placeName><settlement type="city">Rotterdam</settlement>
<region nuts="2" type="province">Hollande-Méridionale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mohan, Viswanathan" sort="Mohan, Viswanathan" uniqKey="Mohan V" first="Viswanathan" last="Mohan">Viswanathan Mohan</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Dr Mohan's Diabetes Specialities Centre</s1>
<s2>Gopalapuram, Chennai</s2>
<s3>IND</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Inde</country>
<wicri:noRegion>Dr Mohan's Diabetes Specialities Centre</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Drugs : (Basel)</title>
<title level="j" type="abbreviated">Drugs : (Basel)</title>
<idno type="ISSN">0012-6667</idno>
<imprint><date when="2012">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Drugs : (Basel)</title>
<title level="j" type="abbreviated">Drugs : (Basel)</title>
<idno type="ISSN">0012-6667</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Biphasic insulin injection</term>
<term>Diabetes mellitus</term>
<term>Human</term>
<term>Hypoglycemic agent</term>
<term>Insulin aspart</term>
<term>Research and development</term>
<term>Review</term>
<term>Symptomatology</term>
<term>Toxicity</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Insuline asparte</term>
<term>Recherche et développement</term>
<term>Soluté injectable d'insuline biphasique</term>
<term>Symptomatologie</term>
<term>Article synthèse</term>
<term>Traitement</term>
<term>Homme</term>
<term>Toxicité</term>
<term>Diabète</term>
<term>Hypoglycémiant</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Recherche et développement</term>
<term>Homme</term>
<term>Diabète</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Biphasic insulin aspart 30 (BIAsp 30) includes 30% soluble rapid-acting insulin aspart (IAsp) along with an intermediate-acting 70% protaminated IAsp that provides coverage of prandial and basal insulin in a single injection. As BIAsp 30 has been available internationally for 10 years, this review provides a comprehensive overview of the discovery of BIAsp 30, its pharmacokinetic and pharmacodynamic profile, safety and efficacy outcomes from the clinical trial programme, 'real-life' clinical insights provided by observational study data, and cost effectiveness and quality-of-life information. These studies have demonstrated that BIAsp 30 once or twice daily is an appropriate option for insulin initiation. BIAsp 30 also provides a switch option in patients on biphasic human insulin (BHI). Switching from BHI to BIAsp 30 is associated with improved postprandial glucose (PPG) and reduced nocturnal and major hypoglycaemia, although daytime hypoglycaemia is higher with BIAsp 30. Intensification of BIAsp 30 can be achieved by increasing the number of daily doses up to three times daily with meals. Therefore, BIAsp 30 provides an intensification option for individuals who are not achieving control with basal insulin and would prefer the simplicity of a single biphasic insulin instead of progressing to a basal-bolus approach. BIAsp 30 has a simple dose-titration algorithm, which enables patients to effectively self-titrate their insulin dose. Cost-effectiveness analyses have demonstrated that BIAsp 30 is cost effective or dominant compared with BHI 30 or insulin glargine in a number of healthcare settings. In conclusion, BIAsp 30 offers a simple and flexible option for insulin initiation and intensification that provides coverage of both fasting and prandial glucose.</div>
</front>
</TEI>
<affiliations><list><country><li>Allemagne</li>
<li>Australie</li>
<li>Danemark</li>
<li>France</li>
<li>Inde</li>
<li>Japon</li>
<li>Pays-Bas</li>
<li>Suisse</li>
</country>
<region><li>Hollande-Méridionale</li>
<li>Région de Kantō</li>
<li>Île-de-France</li>
</region>
<settlement><li>Paris</li>
<li>Rotterdam</li>
<li>Tokyo</li>
</settlement>
</list>
<tree><country name="Allemagne"><noRegion><name sortKey="Liebl, Andreas" sort="Liebl, Andreas" uniqKey="Liebl A" first="Andreas" last="Liebl">Andreas Liebl</name>
</noRegion>
</country>
<country name="Suisse"><noRegion><name sortKey="Prusty, Vinay" sort="Prusty, Vinay" uniqKey="Prusty V" first="Vinay" last="Prusty">Vinay Prusty</name>
</noRegion>
</country>
<country name="France"><region name="Île-de-France"><name sortKey="Valensi, Paul" sort="Valensi, Paul" uniqKey="Valensi P" first="Paul" last="Valensi">Paul Valensi</name>
</region>
</country>
<country name="Japon"><region name="Région de Kantō"><name sortKey="Kawamori, Ryuzo" sort="Kawamori, Ryuzo" uniqKey="Kawamori R" first="Ryuzo" last="Kawamori">Ryuzo Kawamori</name>
</region>
</country>
<country name="Danemark"><noRegion><name sortKey="Christiansen, Jens Sandahl" sort="Christiansen, Jens Sandahl" uniqKey="Christiansen J" first="Jens Sandahl" last="Christiansen">Jens Sandahl Christiansen</name>
</noRegion>
<name sortKey="Balschmidt, Per" sort="Balschmidt, Per" uniqKey="Balschmidt P" first="Per" last="Balschmidt">Per Balschmidt</name>
</country>
<country name="Australie"><noRegion><name sortKey="Palmer, Andrew J" sort="Palmer, Andrew J" uniqKey="Palmer A" first="Andrew J." last="Palmer">Andrew J. Palmer</name>
</noRegion>
</country>
<country name="Pays-Bas"><region name="Hollande-Méridionale"><name sortKey="Ligthelm, Robert" sort="Ligthelm, Robert" uniqKey="Ligthelm R" first="Robert" last="Ligthelm">Robert Ligthelm</name>
</region>
</country>
<country name="Inde"><noRegion><name sortKey="Mohan, Viswanathan" sort="Mohan, Viswanathan" uniqKey="Mohan V" first="Viswanathan" last="Mohan">Viswanathan Mohan</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005859 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 005859 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:12-0426451
   |texte=   Ten Years of Experience with Biphasic Insulin Aspart 30: From Drug Development to the Latest Clinical Findings
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

Serveur d'exploration sur les relations entre la France et l'Australie

Ten Years of Experience with Biphasic Insulin Aspart 30: From Drug Development to the Latest Clinical Findings

Ten Years of Experience with Biphasic Insulin Aspart 30: From Drug Development to the Latest Clinical Findings

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.